Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03651856 · ClinicalTrials.gov registry record · Phase 3
Atomoxetine for Freezing of Gait in Parkinson's Disease
A Phase 3 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
NCT03651856 is a Phase 3 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 10 participants.
The verdict
NCT03651856, a Phase 3 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
Study Summary
Subjects are being asked to participate in this study to determine the safety and effectiveness of a drug called atomoxetine in the treatment of freezing of gait for Parkinson's Disease patients. Atomoxetine (ATM) is an approved drug currently on the market for the treatment of attention deficit. It works to increase the amount of norepinephrine (a chemical in the brain that helps keep us awake and alert) in our brain. ATM has not been approved by the Food and Drug Administration (FDA) to be used in the treatment of PD, but has been found to be well tolerated in this patient population.
Interventions
- DRUG ATM FOG in PD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03651856
The ClinicalTrials.gov registry entry for NCT03651856 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATM FOG in PD is the first listed.
NCT03651856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03651856 about?
NCT03651856 is a clinical study titled "Atomoxetine for Freezing of Gait in Parkinson's Disease". Subjects are being asked to participate in this study to determine the safety and effectiveness of a drug called atomoxetine in the treatment of freezing of gait for Parkinson's Disease patients. Atomoxetine (ATM) is an approved drug currently on the market for the treatment of attention deficit. It...
What is the current status of trial NCT03651856?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2013-01. Estimated completion is 2014-02.
What interventions are being tested in trial NCT03651856?
The interventions under investigation include: ATM FOG in PD (DRUG).
Who is sponsoring clinical trial NCT03651856?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.